Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

SB-205553 used to investigate role of 5-HT2C receptor antagonists in PD therapy

Nov. 13, 1998

SPBN: a free radical scavenger with potential in pediatric head trauma

Nov. 12, 1998

Pharmacological profile of the novel, selective kappa-opioid agonist HZ2

Nov. 12, 1998

Preparation and use of new CNS-active series reported by Pharmacia & Upjohn

Nov. 12, 1998

Improved dosage form of selegiline now on the U.K. market

Nov. 11, 1998

Neuroprotective effects of NCC-161, a new neuronal calcium antagonist

Nov. 11, 1998

Synthelabo presents new 5-HT1A inverse agonist with antagonist and anxiolytic-like activity in vivo

Nov. 11, 1998

PD-161989: novel AMPA/GLYN receptor antagonist related to PNQX

Nov. 11, 1998

Chugai describes inhibitors of iNOS, nNOS

Nov. 11, 1998

Synthelabo presents in vitro, ex vivo and in vivo data on new MAO-B inhibitor

Nov. 11, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...
Circulating sncRNA transcriptome in diabetic kidney disease and SGLT2 inhibitor treatment
BioWorld Science
Small noncoding RNAs (sncRNAs), including miRNAs, piRNAs and snoRNAs, can provide further biological insights into the mechanisms of chronic kidney disease (CKD)...